Results of the National Gynaecological Pathology External Quality Assurance survey
| Question 1 Answer | In your routine reporting of gynaecological cancer specimens which staging system do you use? | |||
| FIGO 64% | TNM 3% | FIGO and TNM 32% | None 1% | |
| Question 2 Answer | In your gynaecological MDT meeting, which staging system is used? | |||
| FIGO 80% | TNM 2% | FIGO and TNM 18% | None 0% | |
| Question 3 Answer | Which staging system do you consider should be used for gynaecological cancers? | |||
| FIGO 54% | TNM 7% | FIGO and TNM 38% | None 0% | |
| Question 4 Answer | Does your MDT group have a preference as to which staging system should be used for gynaecological cancers? | |||
| FIGO 79% | TNM 2% | FIGO and TNM 17% | None 0% | |
| Question 5 Answer | Would you support the use of TNM as well as FIGO staging for selected gynaecological cancers? For example, it has been suggested that TNM is useful for cervical cancers (FIGO does not take into account the lymph-node status in the staging of these neoplasms). | |||
| Yes 81% No 13% | ||||
| Question 6 | Would you support the use of TNM instead of FIGO staging for selected gynaecological cancers bearing in mind the comment in question 5 about TNM being useful for cervical cancers to take into account the lymph-node status? | |||
| Answer | Yes 30% No 69% | |||
FIGO, Fédération Internationale de Gynécologie et d'Obstétrique.